Gazyva
Payments companies reported to CMS as associated with Gazyva. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Gazyva, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Gazyva
These are the largest totals companies reported as associated with Gazyva. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Kevin Winthrop | Portland, OR | Infectious Disease | $20,365.00 |
| Gabriel Contreras | Miami, FL | Nephrology (Internal Medicine) | $9,240.00 |
| Ajay Major | Aurora, CO | Hematology & Oncology | $7,500.00 |
| Amit Saxena | New York, NY | Rheumatology | $6,925.87 |
| Yelena Drexler | Miami, FL | Nephrology (Internal Medicine) | $6,688.47 |
| Isabelle Ayoub | Columbus, OH | Nephrology (Internal Medicine) | $6,559.50 |
| Ladan Zand | Rochester, MN | Nephrology (Internal Medicine) | $6,485.82 |
| Beverly Johnson | Bronx, NY | Rheumatology | $5,894.77 |
| Kimberly Dequattro | Stanford, CA | Rheumatology | $5,775.87 |
| Seema Bhat | Columbus, OH | Hematology (Internal Medicine) | $5,116.71 |
Prescribed Gazyva?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.